SCHEMBL6084701

SCHEMBL6084701

Cc1ccc2nc(-c3c[nH]nc3-c3ccc(NC(=O)C4CC=CCC4NC(=O)OCc4ccccc4)cc3)oc2c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CETP P11597 3/20 0.42
MAPT P10636 8/20 0.41
SMN1; SMN2 Q16637 4/20 0.41
POLB P06746 1/20 0.41
RXFP1 Q9HBX9 1/20 0.39
AGPAT2 O15120 1/20 0.39
TP53 P04637 4/20 0.38
NPC1 O15118 3/20 0.38
RAB9A P51151 3/20 0.38
ALDH1A1 P00352 2/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
BAZ1A Q9NRL2 1/20 0.37
CEPT1 Q9Y6K0 2/20 0.36
PDE3B Q13370 1/20 0.36
PDE3A Q14432 1/20 0.36
HSD17B10 Q99714 2/20 0.36
NPSR1 Q6W5P4 1/20 0.36
THRB P10828 1/20 0.36
KDM4E B2RXH2 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6085163 0.90 CETP (0.42) CETPMAPTSMN1; SMN2POLBRXFP1
SCHEMBL6084524 0.88 CEPT1 (0.43) MAPTSMN1; SMN2RXFP1AGPAT2TP53
SCHEMBL6086315 0.80 CETP (0.44) CETPMAPTSMN1; SMN2POLBRXFP1
SCHEMBL6200627 0.80 HSD17B10 (0.48) MAPTSMN1; SMN2POLBRXFP1TP53
SCHEMBL6085049 0.76 CETP (0.50) CETPMAPTSMN1; SMN2POLBRXFP1
SCHEMBL6085303 0.76 MAPT (0.50) CETPMAPTSMN1; SMN2POLBRXFP1
SCHEMBL6085381 0.75 CETP (0.56) CETPMAPTSMN1; SMN2POLBRXFP1
SCHEMBL6084633 0.74 CETP (0.46) CETPMAPTSMN1; SMN2POLBRXFP1
SCHEMBL6084074 0.73 CTSB (0.40) CETPRAB9AROCK2
SCHEMBL6085906 0.73 MAPT (0.53) CETPMAPTSMN1; SMN2POLBRXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7105535-B2 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2006-09-12 US claimed
EP-1377589-B1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2005-09-07 EP claimed
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2004-09-16 US claimed
EP-1377589-B1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2005-09-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors MAP3K15, MAP3K20, MAP3K3 CETP 4875/4885MAPT 801/4885SMN1; SMN2 831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.